Enanta Pharmaceuticals Inc (ENTA)

[willyw]

I'm still just trying to unpack the first tweet?!?

"Think the RSV study in adults has a high chance to fail"

I thought the data looked good.

" WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 17, 2022-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from its Phase 2 human challenge study has been published in The New England Journal of Medicine (NEJM)."

“The publication of positive results from our Phase 2a human challenge study of EDP-938 in NEJM demonstrates the significance of our work to develop EDP-938 as a potential treatment option for patients with RSV, a deadly virus affecting children, the elderly and the immune compromised for whom there is no vaccine or therapeutic treatment,"

"(and probably little upside if it works)".

There are no great treatments or vaccines for RSV.
PFE just dropped $500 million on a company with RSV treatments in development. The OP's statement confounded me.

" I think patients only present 4+days after inoculation and it's probably too late to show an effect at that point."

I cannot discern what inoculation the OP refers to? Do they think EDP-325 is a vaccine? IF SO.......